Showing results (1081-1090 of 1,217) with videos related to

Sort By:
Pageof 122
Nephron. Clinical Practice|December 15, 2010
An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO studyAngel L M de Francisco, Joseph Kim, Stefan D Anker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 13, 2016
Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique StudyRachel Urquhart-Secord, Jonathan C Craig, Brenda Hemmelgarn, et al.
Genome Biology|April 8, 2020
Principles of RNA processing from analysis of enhanced CLIP maps for 150 RNA binding proteinsEric L Van Nostrand, Gabriel A Pratt, Brian A Yee, et al.
Genome Biology|July 4, 2020
Genomic analysis of the domestication and post-Spanish conquest evolution of the llama and alpacaRuiwen Fan, Zhongru Gu, Xuanmin Guang, et al.
Science Translational Medicine|January 3, 2024
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AMLEmily C Wheeler, Benjamin J E Martin, William C Doyle, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Nature Structural & Molecular Biology|November 1, 2016
RNA-binding protein CPEB1 remodels host and viral RNA landscapesRanjan Batra, Thomas J Stark, Alex E. Clark, et al.
Nature Communications|April 12, 2024
Splice modulators target PMS1 to reduce somatic expansion of the Huntington's disease-associated CAG repeatZachariah L McLean, Dadi Gao, Kevin Correia, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Pageof 122